Answers are grounded in this paper and cite their sources.
Acute myeloid leukaemia (AML) is an aggressive myeloid malignancy characterized by ineffective haematopoiesis. A hallmark of AML is unusual cytogenetic and molecular diversity, which determines treatment and has a major impact on patient response to treatment and survival. The mutations most detected in AML are those in the FMS-like tyrosine kinase 3 gene ( FLT3 ). A case report is presented of a patient with AML with FLT3- ITD mutation who was treated with standard induction and consolidation chemotherapy in combination with midostaurin.
No takes yet. Share an insight, caveat, or question.
Jerzmanowska et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: